One-third of women with breast cancer will develop bone metastases and eventually die from disease progression at these sites. Therefore, we analyzed the ability of human MG-63 osteoblast-like cells 
Introduction
Metastatic breast cancer is the second leading cause of tumor-related death in women after lung cancer (1) . The biology of metastatic breast cancer is unique in that, unlike other solid tumors that metastasize in the skeleton, estrogen receptor positive (ER+) breast cancer patients with bone-only metastases enjoy a favorable response to chemotherapy and favorable prognosis (2) (3) (4) . Unfortunately, this is not the case for patients with ER-breast cancer and/or widespread metastatic disease beyond the skeleton (1, 5) .
Among the most important local modulators involved in the pathophysiology of bone metastases is the urokinase type plasminogen activator (uPA)/plasmin system, which is thought to deregulate bone matrix deposition via activation of metalloproteases and hydrolysis of insulin-like growth factor-binding proteins (IGFBPs), resulting in an increased bioavailability of IGFs and activation of latent transforming growth factor beta 1 (TGF-,31) (6-9). Therefore, the IGFs/IGFBPs/TGF-1 /uPA regulatory system appears to play an important role in mediating cell-cell interactions in bone metastasis. Recently, osteoblasts and osteoblast-derived growth factors, such as IGF-I and TGF-f1, reversed adriamycin apoptosis of metastatic PC-3 prostate cancer cells (10) , and neutralization of type I IGF receptor activity, through tyrosine kinase inhibitors, was associated with a reduction in breast cancer tumor growth (1 1,12 (15) (16) (17) (18) . MG-63 human osteosarcoma cells are well-characterized, osteoblast-like cells that express alkaline phosphatase, osteocalcin, and parathyroid hormone receptor (PTHR). They increase cAMP production in response to PTH and express vitamin D3 receptor and estrogen receptor (ER+). In addition, MG-63 cells increase osteocalcin expression in response to estrogen and enhance expression of type I collagen when cultured on collagen gels (ref. 19 and references therein). In addition, these cell lines were successfully used in the development of a novel three-dimensional type I collagen gel system for studying bone metastases. This system enabled us to produce for the first time morphological evidence of the osteolytic and osteoblastic reaction caused by cell-cell interaction and to analyze apoptosis in vitro (10, (20) (21) (22) (21, 22) , each cell type in the co-culture 3-D system was easily assessed. Results of the analysis were extracted from 10 different sections (number of cells) and were presented as percent above or below the appropriate controls.
Detection of Apoptosis in the 3-D System
After 48 hr of exposure to 100 nM of adriamycin, collagen gels underwent fixation with phosphate-buffered formalin 10% for 4 hr and were then routinely processed and embedded in paraffin blocks. Serial sections of 5 ,m were cut and stained with the classic trichrome-Masson techniques described previously (21, 22) (Fig. 1) .
In addition, a 6-hr exposure to 100 nM of adriamycin produced little change in the phase distribution of MCF-7 and MDA-MB 231 cells and no evidence of apoptosis in both cell cultures (Table 2) . Therefore, exposure to simple agarose gel (Fig. 2) . Consequently, adria- (Table 1) .
Furthermore, the L/D ratio was decreased from 32.8 The 3-D type I collagen system maintained the growth of MCF-7 cells well (Fig. 3a) . The MCF-7 cells were resistant to adriamycin apoptosis in this system (Fig. 4c) . The number of MCF-7 cells decreased by 30% ± S (p < 0.05) after 48 hr exposure to adriamycin compared to controls (Fig. 3b) . Co-culture of MG-63 with MCF-7 cells inhibited growth of both cell types by 40% ± 8 (p < 0.05) compared to control cultures in the 3-D system, which suggests that cell-cell interactions inhibit the growth of both MCF-7 and MG-63 cells (Fig. 3c) . This result is in agreement with a recent report documenting the existence of MCF-7, breast cancer-derived, specific inhibitors of a protein nature (MW = 700 to 4000 D) for osteoblasts, including MG-63 cells (24, 25) . Adriamycin (100 nM) further decreased (55% ± 7; p < 0.05) the number of MCF-7 cells in this 3-D system containing MG-63 osteoblast-like cells compared with that of control cultures using adriamycin-free media.
The 3-D system also maintained the growth of MDA-MB 231 cells (Fig. 5a) . After 48 hr exposure to adriamycin, the number of MDA-MB 231 cells decreased by 45% ±+ 6 (p < 0.05) in the 3-D system (Fig. 5b) . It is noteworthy that the number of MDA-MB 231 cells in the 3 -D systems containing MG-63 cells did not decrease with either the presence of MG-63 cells using adriamycin-free media (Fig. 5c) or the 48-hr exposure to adriamycin, compared to controls (Fig. Sd) . These data suggest that the early establishment of local cell-cell interactions between MG-63 and MDA-MB 231 cells in the 3-D system protects MDA-MB 231 cells from adriamycin cytostasis/apoptosis, thereby promoting the adriamycin-resistant growth of MDA-MB 231 cells in vitro. Fig. 4 Fig. 4a with 4b) 
Discussion
The ability of various neoplasms to metastasize selectively into specific organs depends on metastatic properties of tumor subclones, stochastic elements that interfere with the metastatic process, and local interactions with the host tissue (9, 26, 27 (10) .
The importance of host tissue-tumor interactions in the pathophysiology of bone metastases was recently recognized by analyzing the osteoblastic reaction produced by PC-3 prostate cancer cells (21) , developing morphological evidence of "osteolysis" in response to local growth of MCF-7 and ZR-75 breast cancer cells (22) , and documenting evidence for the angiogenic potential of prostate cancer cells in only the presence of stromal fibroblasts (32) . In addition, interleukin 6 was found to be a resistance factor for etoposide-mediated cytotoxicity of PC-3 and DU145 prostate cancer cells (32) and IGF-I was named as the survival factor of PC 12 cell apoptosis (33) . Furthermore, IGF-I inhibition of the apoptosis of PC12 cells has been associated with an increased expression of the bcl-xL gene product, suggesting that growth factors can regulate apoptosis-related genes, which in turn modulate apoptosis and cell survival (34) . It is noteworthy that a correlation exists between apoptosis, tumorogenicity, and expression of IGF-I/type I IGF receptor (35) (36) (37) . Recently, it has been reported that particular checkpoints in the molecular pathways of apoptosis can meet with growth factor-signal transduction pathways (38, 39) . These checkpoints implicate serine phosphorylation-mediated elimination of a death agonist Bad gene product as a response to survival factors (40) .
In this context, our data suggest that osteoblast-derived growth factors can exert differential influence on ER-MDA-MB-231 and ER+ MCF-7 breast cancer cells, thereby modifying their response to chemotherapy. Conceivably, depending on the type of breast cancer clones, the tumor can acquire either cytotoxic drug-resistant growth in the presence of osteoblast-related growth factors, as exemplified by ER-MDA-MD 231 cells, or a favorable response to chemotherapy, as exemplified by ER' MCF-7 cells. Therefore, it is possible that chemotherapy cytotoxicity is favorably enhanced by bone-derived modifiers in this selective group of patients with advanced ER' breast cancer having boneonly metastases, resulting in favorable prognosis.
